The genetic landscape of autism spectrum disorder in the Middle Eastern population

Front Genet. 2024 Mar 20:15:1363849. doi: 10.3389/fgene.2024.1363849. eCollection 2024.

Abstract

Introduction: Autism spectrum disorder (ASD) is characterized by aberrations in social interaction and communication associated with repetitive behaviors and interests, with strong clinical heterogeneity. Genetic factors play an important role in ASD, but about 75% of ASD cases have an undetermined genetic risk. Methods: We extensively investigated an ASD cohort made of 102 families from the Middle Eastern population of Qatar. First, we investigated the copy number variations (CNV) contribution using genome-wide SNP arrays. Next, we employed Next Generation Sequencing (NGS) to identify de novo or inherited variants contributing to the ASD etiology and its associated comorbid conditions in families with complete trios (affected child and the parents). Results: Our analysis revealed 16 CNV regions located in genomic regions implicated in ASD. The analysis of the 88 ASD cases identified 41 genes in 39 ASD subjects with de novo (n = 24) or inherited variants (n = 22). We identified three novel de novo variants in new candidate genes for ASD (DTX4, ARMC6, and B3GNT3). Also, we have identified 15 de novo variants in genes that were previously implicated in ASD or related neurodevelopmental disorders (PHF21A, WASF1, TCF20, DEAF1, MED13, CREBBP, KDM6B, SMURF1, ADNP, CACNA1G, MYT1L, KIF13B, GRIA2, CHM, and KCNK9). Additionally, we defined eight novel recessive variants (RYR2, DNAH3, TSPYL2, UPF3B KDM5C, LYST, and WNK3), four of which were X-linked. Conclusion: Despite the ASD multifactorial etiology that hinders ASD genetic risk discovery, the number of identified novel or known putative ASD genetic variants was appreciable. Nevertheless, this study represents the first comprehensive characterization of ASD genetic risk in Qatar's Middle Eastern population.

Keywords: autism spectrum disorder (ASD); copy number variation (CNV); de novo mutation; epilepsy; genetics; neurodevelopmental disorders; next-generation sequencing (NGS).

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by start-up grants to OA. from the college of health and life sciences and the Qatar Biomedical Research Institute at Hamad Bin Khalifa University. YA. and EA. are supported by a Ph.D. scholarship from Hamad Bin Khalifa University. The recruitment of patients was initiated by funds from Shafallah Medical Genetics Center and the Shafallah Center for Children with Special Needs. The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of Qatar Biomedical Research Institute (Protocol No.010-002). (As an extension from the IRB of Shafallah).